In vivo RNA interference (RNAi) using small interfering RNA (siRNA) has emerged as a central tool in functional genomics, therapeutic target validation, and disease modeling within living organisms. Unlike in vitro RNAi, which relies on cultured cells, in vivo RNAi allows researchers to explore gene function in a physiologically integrated environment—capturing the complexity of tissue-specific responses, immune interactions, and systemic pharmacokinetics. This capability makes in vivo siRNA delivery particularly valuable in cancer biology, metabolic research, infectious disease models, and neurobiology.
Biological Barriers to In Vivo siRNA Delivery
siRNA molecules, when delivered systemically, encounter a series of biological barriers that limit their bioavailability and functional impact. These include degradation by serum nucleases, renal clearance due to their small molecular size, non-specific uptake by the mononuclear phagocyte system (particularly in the liver and spleen), and entrapment in endosomal compartments after cellular internalization. Additionally, innate immune sensors such as Toll-like receptors (TLR3, TLR7, TLR8), RIG-I, and MDA5 can recognize siRNA as foreign RNA, triggering unwanted cytokine release and inflammation.
Strategies for Enhancing Stability and Delivery Efficiency
Chemical modifications of siRNA enhance resistance to enzymatic degradation and reduce immunogenicity. Common approaches include 2′-O-methylation of the ribose sugar, phosphorothioate linkages in the backbone, and incorporation of locked nucleic acids (LNAs). Terminal conjugation with lipophilic or targeting ligands—such as cholesterol, GalNAc (for hepatocyte-specific uptake), folate, or transferrin—can improve tissue penetration and receptor-mediated uptake. In parallel, encapsulation in delivery vehicles like lipid nanoparticles (LNPs), polymeric micelles, dendrimers, or liposomes provides additional protection and enables formulation-specific tissue distribution.
Tissue Targeting via Ligand Conjugation and Nanocarriers
Selective accumulation of siRNA in target tissues is achieved by exploiting tissue-specific surface receptors. GalNAc-siRNA conjugates target hepatocytes via the asialoglycoprotein receptor, while RGD peptides can target integrins overexpressed in tumor vasculature. Antibody–RNA conjugates and aptamer-linked carriers are also used for delivery to cancer cells, immune subsets, and endothelial tissues. Once localized, siRNA uptake relies on receptor-mediated endocytosis followed by efficient endosomal escape.
Endosomal Escape: A Critical Bottleneck
After cellular uptake, a key limiting step in functional RNAi is cytoplasmic release of the siRNA duplex. Ionizable lipids in LNP formulations become positively charged in the acidic environment of endosomes, promoting membrane fusion and content release. Other delivery systems incorporate pH-sensitive polymers, fusogenic peptides, or membrane-disruptive elements to improve endosomal escape. Less than 2% of internalized siRNA typically reaches the cytosol, making this a priority in delivery system design.
Routes of Administration and Pharmacokinetics
In vivo siRNA can be administered via various routes depending on the target tissue. Intravenous injection provides systemic exposure and is useful for hepatic or tumor targeting. Intratumoral injection ensures high local concentration in solid tumors, while intranasal, intraperitoneal, or subcutaneous routes may be employed for lung, peritoneal, or skin-accessible tissues, respectively. Particle size, surface charge, PEGylation, and ligand decoration influence circulation time and tissue distribution.
Applications in Preclinical Research and Therapeutic Studies
In vivo RNAi is frequently used in animal models to evaluate the function of candidate genes, investigate disease mechanisms, and explore therapeutic modulation. It enables transient gene silencing in xenograft tumor models, genetically engineered mouse models (GEMMs), or infection models. Validated knockdown is typically confirmed via qRT-PCR, Western blotting, or immunohistochemistry, with functional outcomes assessed through phenotypic assays or survival studies. Additionally, in vivo RNAi supports pharmacodynamic biomarker development and the identification of resistance pathways in drug-treated tumors.
Designing Robust In Vivo RNAi Experiments
Experimental success depends on optimizing siRNA sequence specificity, delivery formulation, dose scheduling, and immune evasion. Proper controls—including scrambled siRNA sequences, vehicle-only groups, and untreated controls—are necessary to distinguish specific gene silencing effects from off-target or procedural artifacts. Endpoints must be carefully selected based on the gene of interest and its role in the disease phenotype.
Access Professional In Vivo RNAi Services
For researchers requiring expert support in in vivo siRNA delivery, professional services are available that offer end-to-end solutions from siRNA design to in vivo administration and endpoint analysis. These services typically include formulation development (e.g., liposomal or nanoparticle encapsulation), tissue-specific targeting strategies, and customized dosing regimens. The use of validated delivery protocols and established animal models ensures reliable and reproducible knockdown results.
Altogen Labs offers an advanced in vivo RNAi service that includes siRNA formulation, delivery route optimization, and downstream molecular and phenotypic analysis. Their services support gene knockdown in tumor xenograft models, normal tissues, and hard-to-target organ systems using state-of-the-art delivery platforms. More information is available on their dedicated service page.